Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Aspas Requena G.
  • Gil C.
  • Botella C.
  • Aguiar E.
  • Trigo F.
  • Colorado M.
  • del Bernal del Castillo T.
  • Tormo M.
  • Rodríguez Arbolí E.
  • Serrano López J.
  • García Boyero R.
  • Castaño T.
  • Herrera Puente P.
  • Romero Riquelme M.A.
  • Sayas Lloris M.J.
  • Algarra-Algarra L.
  • Rodriguez-Medina C.
  • Sossa Melo C.L.
  • Labrador Gomez J.
  • Vives S.
  • Salamero O.
  • Amigo M.L.
  • Valero Nuñez M.
  • Rojas C.
  • Bass F.
  • García-Fortes M.
  • Vidriales Vicente B.
  • Polo M.
  • Benavente C.
  • Madrigal M.D.
  • Espinoza M.
  • Pérez-Encinas M.
  • Amador Barciela M.L.
  • Bautista G.
  • Colmenares R.
  • García-Ramírez P.
  • Ibáñez Alis F.
  • Barrios García M.
  • Rodríguez-Macías G.
  • López M.
  • Oliva Hernández A.Y.
  • Cerveró C.J.
  • Bergua Burgues J.M.

Grupos

Abstract

In a large multicenter real-world cohort, we aimed to evaluate outcomes of FLAG-Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary refractory disease (36.9%) and first relapse episode (63.1%), with a median age of 52 years. Complete remission composite (CRc) was achieved 56.8%, including complete remission (CR) in 51.0%, CR with incomplete recovery in 4.0%, and morphological-free-state in 1.8%, enabling 35.2% of patients and 62% of responders to proceed to allogeneic transplantation without morphological disease. With median follow-up of 50.9 months, median overall survival (OS) was 10.2 months, with 5-year OS rate of 21.6%. Prior allogeneic transplantation (HR 0.54; p < 0.001) and relapse-free interval = 1 year (HR 0.75; p = 0.024) independently predicted improved OS, whereas modified high-risk cytogenetics including t(8; 21) (HR 3.58; p < 0.001), FLT3-ITD mutation at primary diagnosis (HR 1.61; p < 0.001), and age = 60 (HR 1.43; p < 0.001) conferred inferior OS. Validation of the SALFLAGE score demonstrated moderate discrimination (C-index 0.67), with 5-year survival of 38.4%, 27.2%, and 12.7% across risk categories (p < 0.001). Outcomes improved over periods (1998–2005 vs. 2006–2016 vs. 2017–2024): 30-day mortality was 6.9% vs. 9.3% vs. 5.0%, respectively (p = 0.030), and median OS was 7.8 versus 9.4 versus 11.1 months, respectively (p = 0.16). We confirm FLAG-Ida as a reference salvage regimen in fit R/R AML and validate the SALFLAGE score in this setting. © 2026 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.

Datos de la publicación

ISSN/ISSNe:
0361-8609, 1096-8652

AMERICAN JOURNAL OF HEMATOLOGY  WILEY

Tipo:
Article
Páginas:
1692-1705
PubMed:
42017547
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,600 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 1

Citas Recibidas en Scopus: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acute myeloid leukemia; FLAG-Ida; real-world; relapsed/refractory; salvage therapy

Compartir